Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride

Small Cell Lung Cancer Clinical Trial

Official title:

Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03890055
• Other study ID #: B19267BT
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: April 1, 2019
• Est. completion date: October 1, 2020

Study information

• Verified date: March 2019
• Source: Chifeng Municipal Hospital
• Contact: Hongbo JI, postgraduate
• Phone: 18604868579
• Email: docjihongbo[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was designed to investigate the efficacy and side effects of combining erlotinib with classical EC/EP chemotherapy regimens.

Description:

Lung cancer is a common malignant tumor that poses a serious threat to human health. Small cell lung cancer accounts for about 20% of lung cancer. Precision medicine has recently been perfectly interpreted in many tumor types, but the treatment of small cell lung cancer is still bleak. The EC/EP regimen is the most classic chemotherapy regimen for small cell lung cancer with good results but is prone to drug resistance. In 2018, with the development of immunotargeting therapy, small molecule multi-target anti-angi drugs, PARP inhibitors, new chemotherapy drugs, etc., the treatment of small cell lung cancer has ushered in a new dawn. As a kind of highly selective multi-target anti-angiogenic TKI drugs,Anlotinib Hydrochloride is a kind of 1.1 innovative drugs with independent intellectual property rights in China, mainly acting on VEGFR, PDGFR, FGFR and c-Kit. The latest ALTER1202 study confirms that anlotinib is significantly improved for PSC and ORR in SCLC patients who have previously received at least 2-line chemotherapy. OS data is not yet mature, but the benefits of the anlotinib group were observed. The adverse effects of anlotinib were consistent with expectations, no new adverse events were found, and safety was tolerated. Nowadays, the effective combination of traditional chemical therapy with molecular targeting and immunotherapy is the future development direction of lung cancer treatment. Therefore, this topic is designed to combine the efficacy of safety and safety with the treatment of anlotinib with the classic EC/EP chemotherapy regimen. Expected to get longer PFS and OS for patient benefit.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: October 1, 2020
• Est. primary completion date: April 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. patients 18-75 years of age.

2. A metastatic or recurrent advanced SCLC confirmed by histology or cytology and did not receive any other treatment;

3. a measurable disease

4. an Eastern Cooperative Oncology Group PS of 0-1;

5. an estimated survival duration of >6 months;

Exclusion Criteria:

1. Have used erlotinib or other anti-vascular targeted drugs (eg, Endo, bevacizumab, etc.)2. Patients who have been treated with chemotherapy or radiotherapy for previous tumors.3.Have appeared or merged with other tumors within 5 years.4.Patients with no measurable lesions; 5.any severe and uncontrolled disease.

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer
• Small Cell Lung Carcinoma

Intervention

Drug:
• Anlotinib Hydrochloride
Best supportive care

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Chifeng Municipal Hospital

References & Publications (1)

Han JY, Kim HY, Lim KY, Han JH, Lee YJ, Kwak MH, Kim HJ, Yun T, Kim HT, Lee JS. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer. 2013 Feb;79(2):137-42. doi: 10.1016/j.lungcan.2012.09.019. Epub 2012 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	progression-free survival	nine months
Secondary	OS	overall survival	12 months
Secondary	ORR	Objective Response Rate	12 months
Secondary	DCR	disease control rate	12 months
Secondary	safety assessed by Adverse reactions	Adverse reactions	12 months

External Links

•   National Institutes of Heaith